Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
Bicara Therapeutics’ $108 Million Series B Financing
SonoThera’s $60.75 Million Series A Funding
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Entrada Therapeutics’ Global Collaboration with Vertex Pharmaceuticals Incorporated
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
Nimbus Therapeutics’ Research Collaboration and License Agreement with Eli Lilly and Co.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
Sarepta Therapeutics’ $1.15 Billion Notes Offering
Goodwin Procter advised the initial purchasers on the deal. Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion...
Wayfair’s $690 Million Convertible Senior Notes Offering
Goodwin Procter represented Wayfair, while Davis Polk advised the representatives of the initial purchasers in the offering. Wayfair Inc. completed its offering of $690 million aggregate principal...
Alnylam Pharmaceuticals’ $1.035 Billion Notes Offering
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...
Ampersand Capital Partners’ $1.2 Billion Closing of Latest Fund
Goodwin Procter advised Ampersand Capital Partners on the deal. Ampersand Capital Partners announced its first and only closing of Ampersand 2022 Limited Partnership with $1.2 billion in...
Q32 Bio’s Collaboration and Option Agreement with Horizon Therapeutics Ireland DAC
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
Carlyle and Abingworth’s $170 Million Non-dilutive Financing of Opthea
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...